NASDAQ · SXTC
China SXT Pharmaceuticals financials
$2.81+11.51%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Mar 31 | FY25 Mar 31 | FY24 Mar 31 | FY23 Mar 31 | FY22 Mar 31 | FY21 Mar 31 | FY20 Mar 31 | FY19 Mar 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $1.7M | $1.9M | $2.0M | $2.6M | $4.8M | $5.2M | $7.0M |
| Gross profit | $248.7K | $367.4K | $554.0K | $426.3K | $1.3M | $2.8M | $2.7M | $4.6M |
| Gross margin | 21.9% | 21.1% | 28.7% | 21.6% | 48.1% | 59.4% | 52.4% | 65.8% |
| Operating income | -$6.1M | -$2.7M | -$2.6M | -$5.6M | -$5.4M | -$2.2M | -$1.3M | $1.8M |
| Net income | -$6.2M | -$3.3M | -$3.1M | -$5.9M | -$5.7M | -$2.7M | -$10.3M | $1.5M |
| Net margin | −545.2% | −189.8% | −160.7% | −301.0% | −220.4% | −57.5% | −199.3% | 22.0% |
| Diluted EPS | $-730.40 | $-27853.60 | $-342852.80 | $-2134044.00 | $-13240128.00 | $-9165600.00 | $-79876800.00 | $14352000.00 |
| EBITDA | -$6.1M | -$2.6M | -$2.4M | -$5.4M | -$4.5M | -$1.9M | -$1.0M | $2.0M |
| Operating cash flow | -$4.0M | -$2.3M | -$1.9M | -$80.8K | $268.3K | -$1.3M | $934.2K | $366.2K |
| Free cash flow | -$4.0M | -$2.3M | -$1.9M | -$80.8K | $266.7K | -$1.3M | $527.6K | -$232.6K |
| Diluted shares | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M | 0.0M |
Balance sheet
| Period end | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $28.2M | $18.1M | $12.1M | $17.4M | $15.5M | $13.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $999.6K | $807.2K | $2.4M | $3.5M | $11.4K | $43.4K |
| Total assets | $34.8M | $21.7M | $23.1M | $29.6M | $33.5M | $34.5M |
| Total liabilities | $5.0M | $6.2M | $9.2M | $14.9M | $17.1M | $18.6M |
| Shareholders' equity | $29.7M | $15.4M | $13.9M | $14.7M | $16.4M | $16.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology